Skip to content

Beam Therapeutics BEAM Income Statement

FY'25FY'24FY'23FY'22
$139.74M+120%$63.52M-83.2%$377.71M+520%$60.92M+17.5%
$409.62M+11.4%$367.56M-16.0%$437.38M+40.4%$311.59M-19.5%
$113.82M+2.1%$111.53M-4.5%$116.81M+33.0%$87.81M+53.4%
$523.44M+9.3%$479.09M-13.6%$554.19M+38.8%$399.4M-10.1%
-$383.69M+7.7%-$415.57M-$338.48M+13.8%
-274.6%+380pp-654.3%-555.6%+201pp
$304.64M+684%$38.87M-14.3%$45.32M-42.1%$78.3M+240%
-$376.74M-$289.09M+22.0%
-$4.58-$4.13+30.1%
-$361.4M+8.2%-$393.64M-$324.33M+15.8%
-258.6%+361pp-619.7%-532.4%+210pp
-$383.69M+7.7%-$415.57M-$338.48M+13.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is Beam Therapeutics's revenue?
Beam Therapeutics (BEAM) generated $164.0M in revenue over the trailing twelve months, up 158.0% year over year.
Is Beam Therapeutics profitable?
Beam Therapeutics is not currently profitable: it reported a net loss of $417.7M over the trailing twelve months, a -742.7% net margin.
What is Beam Therapeutics's earnings per share?
Beam Therapeutics's diluted EPS over the trailing twelve months is $-4.24.
Where does Beam Therapeutics's income statement data come from?
Every line is extracted from Beam Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.